Palosuran

HCID 10173280

기본 정보

CAS
540769-28-6
표준 SMILES
Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1
InChIKey
WYJCYXOCHXWTHG-UHFFFAOYSA-N
분자식
C25H30N4O2
평균 분자량
418.5 g/mol
단동위원소 질량
418.23687621

이름 및 식별자

우선 이름
Palosuran
IUPAC
1-[2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl]-3-(2-methylquinolin-4-yl)urea
영어명
Urea, N-[2-[4-hydroxy-4-(phenylMethyl)-1-piperidinyl]ethyl]-N'-(2-Methyl-4-quinolinyl)-
분자식
C25H30N4O2
분자량
418.53

이름 및 동의어

Palosuran540769-28-6ACT-0583621-(2-(4-Benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(2-methylquinolin-4-yl)ureaULD9ZKE4571-[2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl]-3-(2-methylquinolin-4-yl)ureaDTXSID002024061-[2-[4-hydroxy-4-(phenylmethyl)piperidin-1-yl]ethyl]-3-(2-methylquinolin-4-yl)ureapalosuranum1-(2-(4-hydroxy-4-(phenylmethyl)piperidin-1-yl)ethyl)-3-(2-methylquinolin-4-yl)ureaRefChem:169773DTXCID60124897
이름 더 보기
ACT 058362PALOSURAN,, >98%Palosuran (ACT058362)ACT 058362PALOSURAN,Palosuran, 10 mM in DMSOACT 058362PALOSURAN,, >98%N-[2-[4-Hydroxy-4-(phenylmethyl)-1-piperidinyl]ethyl]-N'-(2-methyl-4-quinolinyl)urea
ACT0583621-(2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(2-methylquinolin-4-yl)urea sulfate saltPalosuran [INN]ACT058362 (Palosuran)CHEMBL567303GTPL3516MFCD07772352Urea, N-[2-[4-hydroxy-4-(phenylMethyl)-1-piperidinyl]ethyl]-N'-(2-Methyl-4-quinolinyl)-

데이터베이스 식별자

CAS
540769-28-6
PubChem CID
10173280
DTXSID
DTXSID00202406
ChEMBL
CHEMBL567303
UNII
ULD9ZKE457
Nikkaji
J2.917.197A

물성

구조 계산 물성

XLogP
3.3
극성 표면적
77.5 Ų
수소 결합 공여자 수
3
수소 결합 수용자 수
4
회전 가능 결합 수
6
무거운 원자 수
31

물리화학적 성질

끓는 점
612.9 · 612.9±55.0 °C(Predicted)
밀도
1.235 · 1.235±0.06 g/cm3(Predicted)
저장 조건
-20 °C · Store at -20°C
용해도
10 mg/ml; · DMF: 10 mg/ml; DMSO: 10 mg/ml; DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml; Ethanol: 0.5 mg/ml
물리적 상태
결정성 고체
산도 계수 (pKa)
12.95 · 12.95±0.43(Predicted)

안전 및 규제

안전 데이터

wgk
WGK 3
스토리지 클래스
11 - Combustible Solids

화학 및 산업

응용 분야 · 1건

개요Palosuran is an antagonist of the urotensin II receptor (UTR; IC50s = 3.6 and 1,475 nM for CHO cell membranes expressing human and rat recombinant receptors, respectively). It inhibits contraction of isolated rat aortic rings induced by urotensin II (Item Nos. 24711 | 24753) in a concentration-dependent manner. Palosuran (300 mg/kg twice per day) reduces plasma endothelin-1 , urotensin II, and TGF-β1 levels, as well as the main pulmonary arterial pressure and right ventricular hypertrophy index in a rat model of pulmonary arterial hypertension (PAH) induced by monocrotaline . Palosuran (300 mg/kg per day) reduces serum glucose, cholesterol, and triglyceride levels and increases survival in a rat model of diabetes induced by streptozotocin (STZ; ). It also decreases albuminuria and global kidney lesion scores in STZ-induced diabetic rats.

공급사55 곳

Career Henan Chemica Co+86-0371-86658258 +86-13203830695 · [email protected]
武汉英诺医药科技有限公司+86-027-59232304 15387063101 · [email protected]
成都超九八生物科技有限公司13348960310 13348960310 · [email protected]
江苏艾康生物医药研发有限公司025-58851090 19370895928 · [email protected]
上海毕得医药科技股份有限公司400-1647117 13681763483 · [email protected]

관련 반응

7건

화합물 노트

불러오는 중…